Clover Health Files 8-K for Reg FD and Exhibits
Ticker: CLOV · Form: 8-K · Filed: May 29, 2024 · CIK: 1801170
| Field | Detail |
|---|---|
| Company | Clover Health Investments, Corp. /De (CLOV) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulation-fd, exhibits
Related Tickers: CLOV
TL;DR
CLOV filed an 8-K, standard stuff, no major news.
AI Summary
Clover Health Investments Corp. filed an 8-K on May 29, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Clover Health is adhering to its reporting obligations with the SEC, providing updates on financial statements and regulatory disclosures.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any new material risks or events.
Key Players & Entities
- CLOVER HEALTH INVESTMENTS, CORP. (company) — Registrant
- 0001801170-24-000119 (filing_id) — Accession Number
- May 29, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 3401 Mallory Lane, Suite 210 Franklin, Tennessee 37067 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Clover Health Investments, Corp.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
On what date was this 8-K filing reported?
This 8-K filing was reported on May 29, 2024.
What is the state of incorporation for Clover Health Investments, Corp.?
Clover Health Investments, Corp. is incorporated in Delaware.
What is the address of Clover Health's principal executive offices?
The address of Clover Health's principal executive offices is 3401 Mallory Lane, Suite 210, Franklin, Tennessee 37067.
Does this 8-K filing announce any new material events or financial results?
This 8-K filing primarily serves as a notification for Regulation FD Disclosure and the filing of Financial Statements and Exhibits, and does not appear to announce specific new material events or financial results within the provided text.
Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-05-29 08:02:43
Key Financial Figures
- $0.0001 — stered Class A Common Stock, par value $0.0001 per share CLOV The NASDAQ Stock Market
Filing Documents
- clov-20240529.htm (8-K) — 28KB
- exhibit991-pressreleasedat.htm (EX-99.1) — 15KB
- exhibit992-cloverhealthi.htm (EX-99.2) — 8KB
- exhibit992-cloverhealthi001.jpg (GRAPHIC) — 37KB
- exhibit992-cloverhealthi002.jpg (GRAPHIC) — 178KB
- exhibit992-cloverhealthi003.jpg (GRAPHIC) — 98KB
- exhibit992-cloverhealthi004.jpg (GRAPHIC) — 125KB
- exhibit992-cloverhealthi005.jpg (GRAPHIC) — 124KB
- exhibit992-cloverhealthi006.jpg (GRAPHIC) — 82KB
- exhibit992-cloverhealthi007.jpg (GRAPHIC) — 22KB
- 0001801170-24-000119.txt ( ) — 1102KB
- clov-20240529.xsd (EX-101.SCH) — 2KB
- clov-20240529_lab.xml (EX-101.LAB) — 22KB
- clov-20240529_pre.xml (EX-101.PRE) — 13KB
- clov-20240529_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 29, 2024, Clover Health Investments, Corp. (the "Company") issued a press release announcing that Clover Assistant, its flagship clinical decision support tool, is now generally available for external payors and providers under the brand name Counterpart Assistant. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. A copy of an investor presentation with supplemental information regarding this announcement is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information set forth in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) List of Exhibits Exhibit No. Description 99.1 Press release dated May 29, 2024 99.2 Investor Presentation dated May 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Clover Health Investments, Corp. Date: May 29, 2024 By: /s/ Peter Kuipers Name: Peter Kuipers Title: Chief Financial Officer